A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs Baloxavir-marboxil (Primary) ; Oseltamivir; Peramivir; Zanamivir
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 08 Nov 2019 Planned End Date changed from 10 Jul 2021 to 27 Mar 2021.
- 08 Nov 2019 Planned primary completion date changed from 10 Jul 2021 to 27 Mar 2021.
- 23 Jul 2019 Planned number of patients changed from 240 to 366.